Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016-Reference-Cited by-同舟云学术

Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016

Published:2018-10 Issue:40 Volume:97 Page:e12715
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Roginiel Aliya C.,Dhruva Sanket S.,Ross Joseph S.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference11 articles.

1. Benefit-risk assessments at the US food and drug administration: finding the balance;Califf;JAMA,2017

2. Medicare program; revised process for making national coverage determinations;Sebelius;Dep Health Hum Serv Cent Medicare Medicaid Services Federal Register,2013

3. Factors predicting medicare national coverage: an empirical analysis;Chambers;Med Care,2012

4. Medicare is scrutinizing evidence more tightly for national coverage determinations;Chambers;Health Aff Millwood,2015

5. Characteristics of clinical studies conducted over the total product life cycle of high-risk therapeutic medical devices receiving fda premarket approval in 2010 and 2011;Rathi;JAMA,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Funding of evidence included within public comments submitted to inform Medicare national coverage determinations;Health Affairs Scholar;2024-05-13

3. Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics;American Journal of Therapeutics;2024-03

4. Aligning US Agency Policies for Cardiovascular Devices Through the Breakthrough Devices Program;JAMA Cardiology;2023-12-01

5. Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC;Journal of the National Comprehensive Cancer Network;2023-12